Abstract
Hyperhidrosis is defined as sweating amounts larger than necessary to maintain normal body thermoregulation. This condition can affect the patient’s quality of life by way of its psychological and social impact. The central nervous system (cortex, hypothalamus, medulla) and sweat glands, including the eccrine, apocrine, and apoeccrine, are involved in the physiopathology of this condition. Hyperhidrosis can be divided into primary and secondary, and is also associated with a wide variety of conditions. Treatments to alleviate this disorder include topical products (aluminum compounds), iontophoresis, oral treatment with anticholinergic agents (glycopyrrolate, clonidine, oxybutynin), and interventional procedures such as botulinum toxin A, sweat gland removal (suction or curettage), microfocused ultrasound, and sympathectomy. Understanding the clinical features of this disorder and treatment modalities is vital to the optimization of treatment for affected patients.
References
Leung AK, Chan PYH, Choi MCK. Hyperhidrosis. Int J Dermatol. 1999;38:5617.
Walling HW. Primary hyperhidrosis increases the risk of cutaneous infection: a case control study of 387 patients. J Am Acad Dermatol. 2009;61(2):242–6.
Lasek RJ, Chren MM. Acne vulgaris and the quality of life of adult dermatology patients. Arch Dermatol. 1998;134:454–8.
Higaki Y, Kawamoto K, Kamo T, Horikawa N, Kawashima M, Chren MM. The Japanese version of Skindex-16: a brief quality-of-life measure for patients with skin diseases. J Dermatol. 2002;29:693–8.
Walling HW. Clinical differentiation of primary from secondary hyperhidrosis. J Am Acad Dermatol. 2011;64(4):690–5.
Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004;51:241–8.
Fujimoto T, Kawahara K, Yokozeki H. Epidemiological study and considerations of primary focal hyperhidrosis in Japan: from questionnaire analysis. J Dermatol. 2013;40:886–90.
Augustin M, Radtke MA, Herberger K, Kornek T, Heigel H, Schaefer I. Prevalence and disease burden of hyperhidrosis in the adult population. Dermatology. 2013;227:10–3.
Stefaniak T, Tomaszewski KA, Proczko-Markuszewska M, Idestal A, Royton A, Abi-Khalil C. Is subjective hyperhidrosis assessment sufficient enough? Prevalence of hyperhidrosis among young Polish adults. J Dermatol. 2013;40:819–23.
Lear W, Kessler E, Solish N, Glaser DA. An epidemiological study of hyperhidrosis. Dermatol Surg. 2007;33:S69–75.
Ro KM, Cantor RM, Lange KL, Ahn SS. Palmar hyperhidrosis: evidence of genetic transmission. J Vasc Surg. 2002;35(2):382–6.
Quinton PM, Elder HY, Jenkinson DME, et al. Structure and function of human sweat glands. In: Laden K, editor. Antiperspirants and deodorants. New York: Marcel Dekker; 1999. p. 17–57.
Bovell DL, Clunes MT, Elder HY, Milsom J, Jenkinson DM. Ultrastructure of the hyperhidrotic eccrine gland. Br J Dermatol. 2001;145:298–301.
Dobson RL. The human eccrine gland. Arch Environ Health. 1965;2:423–9.
Sato K, Kang WH, Saga K, Sato KT. Biology of sweat glands and their disorders. I. Normal sweat glands function. J Am Acad Dermatol. 1989;20:537–63.
Hurley HJ, Witkowski JA. The dynamics of the eccrine sweating in man. I. Sweat delivery through myoepithelial contraction. J Invest Dermatol. 1962;39:329–38.
Lonsdale-Eccles A, Leonard N, Lawrence C. Axillary hyperhidrosis: eccrine or apocrine? Clin Exp Dermatol. 2003;28:2–7.
Lakraj AD, Moghimi N, Jabbari B. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins. Toxins (Basel). 2013;5:821–40.
Elder DE, Elenitsas R, Rosenbach M, Murphy GF, Rubin AI, Xu X. Lever’s histopathology of the skin. 11th ed. Philadelphia: Press: Lippincott Williams & Wilkins; 2014.
Sato K, Ohtsuyama M, Samman G. Eccrine sweat gland disorders. J Am Acad Dermatol. 1991;24(6):1010–4.
Naumann M. Hypersecretory disorders. In: Moore P, Naumann M, editors. Handbook of botulinum toxin treatment. 2nd ed. Oxford: Blackwell-Science; 2003. p. 343–59.
Sato K, Sato F. Effect of VIP on sweat secretion and cAMP accumulation in isolated simian eccrine glands. Am J Phys. 1987;253:R935–41.
Saadia D, Voustianiouk A, Wang AK, Kaufmann H. Botulinum toxin type a in primary palmar hyperhidrosis: randomized, single-blind, two-dose study. Neurology. 2001;57:2095–9.
Smith FC. Hyperhidrosis. Vasc Surg. 2013;31(5):251–5.
Schnider P, Binder M, Kittler H, Birner P, Starkel D, Wolff K, et al. A randomized, double-blind, placebo-controlled trial of botulinum a toxin for severe axillary hyperhidrosis. Br J Dermatol. 1999;140:677–80.
Champion RH. Disorders of sweat glands. In: Champion RH, Burton JL, Ebling FJG, eds. Textbook of Dermatology. 5th edn. Oxford: Blackwell, 1992;3:1758–9.
Almeida AT, Boraso RZ. Palmar hyperhidrosis. In: Almeida AT, Hexsel D, editors. Hyperhidrosis and botulinum toxin. SĂ£o Paulo: Author’s Edition; 2003. p. 167–74.
Hexsel D, Ave BR, Hexsel C, Dal Forno T. Inguinal hyperidrosis. In: Almeida AT, Hexsel D, editors. Hyperhidrosis and botulinum toxin. SĂ£o Paulo: Author’s Edition; 2003. p. 181–5.
Hexsel DM, Dal’Forno T, Hexsel CL. Inguinal, or Hexsel’s hyperhidrosis. Clin Dermatol. 2004;22:53–9.
Kreyden OP, Schmid-Grendelmeier P, Burg G. Idiopathic localized unilateral hyperhidrosis. Case report of successful treatment with Botulinum Toxin Type A and review of the literature. Arch Dermatol. 2001;137:1622–5.
Kocyigit P, Akay BN, Saral S, Akbostanci C, Bostanci S. Unilateral hyperhidrosis with accompanying contralateral anhidrosis. Clin Exp Dermatol. 2009;34:e544–6.
Glaser DA, Herbert AA, Pariser DM, Solish N. Primary focal hyperhidrosis: scope of the problem. Cutis. 2007;79(5):5–17.
Chopra KF, Evans T, Severson J, Tyring SK. Acute varicella zoster with postherpetic hyperhidrosis as the initial presentation of HIV infection. J Am Acad Dermatol. 1999;41:119–21.
Connor KM, Cook JL, Davidson JR. Botulinum toxin treatment of social anxiety disorder with hyperhidrosis: a placebo-controlled double-blind trial. J Clin Psychiatry. 2006;67:30–6.
Davidson JR, Foa EB, Connor KM, Churchill LE. Hyperhidrosis in social anxiety disorder. Prog Neuro-Psychopharmacol Biol Psychiatry. 2002;26:1327–31.
Ruchinskas R. Hyperhidrosis and anxiety: chicken or egg? Dermatology. 2007;214:195–6.
Shaw JE, Parker R, Hollis S, Gokal R, Boulton AJ. Gustatory sweating in diabetes mellitus. Diabet Med. 1996;13:1033–7.
Blair D, Sagel J, Taylor I. Diabetic gustatory sweating. South Med J. 2002;95(3):360–2.
de Bree R, Van der Waal I, Leemans R. Management of Frey syndrome. Head Neck. 2007;29(8):773–8.
Baskan EM, Karli N, Baykara M, et al. Localized unilateral hyperhidrosis and neurofibromatosis type I: case report of a New Association. Dermatology. 2005;211:286–9.
Almeida AT, Boraso RZ. Palmar hyperhidrosis. In: Almeida AT, Hexsel D, editors. Hyperhidrosis and botulinum toxin. SĂ£o Paulo: Author’s Edition; 2003. p. 41–56.
Dua J, Grabczynska S. Eccrine nevus affecting the forearm of an 11-year-old girl successfully controlled with topical glycopyrrolate. Pediatr Dermatol. 2014;31(5):611–2.
Sen S, Chatterjee G, Mitra PK, Gangopadhyay A. Eccrine angiomatous naevus revisited. Indian J Dermatol. 2012;57(4):313–5.
Shah S, Boen M, Kenner-Bell B, Schwartz M, Rademaker A, Paller AS. Pachyonychia congenital in pediatric patients: natural history, features and impact. JAMA Dermatol. 2014;150(2):146–53. epublished:E1–7.
Biju V, Sawhney MP, Vishal S. Ross syndrome with ANA positivity: a clue to possible autoimmune origin and treatment with intravenous immunoglobulin. Indian J Dermatol. 2010;55(3):274–6.
Ballestero-Diez M, Garcia-Rio I, Dauden E, Corrales-Arroyo M, GarcĂa-DĂez A. Ross Syndrome, an entity included within the spectrum of partial disautonomic syndromes. J Eur Acad Dermatol Venereol. 2005;19:729–31.
Lyra Rde M, Campos JR, Kang DW, Loureiro MP, Furian MB, Costa MG, et al. Guidelines for the prevention, diagnosis and treatment of compensatory hyperhidrosis. J Bras Pneumol. 2008;34(11):967–77.
Cerfolio RJ, Milanez de Campos JR, Bryant AS, Connery CP, Miller DL, de Camp MM, et al. The Society of Thoracic Surgeons expert consensus for the surgical treatment of hyperhidrosis. Ann Thorac Surg. 2011;91:1642–8.
Drott C, Gothberg G, Claes G. Endoscopic transthoracic sympathectomy: an efficient and safe method for the treatment of hyperhidrosis. J Am Acad Dermatol. 1995;33:78–81.
Yazar S, Aslan C, Serdar ZA, Demirci GT, Tutkavul K, Babalik D. Ross syndrome: Unilateral hyperhidrosis, Adie’s tonic pupils and diffuse areflexia. J Dtsch Dermatol Ges. 2010;8:1004–6.
Saito H, Sakuma H, Seno K. A case of traumatic high thoracic myelopathy presenting dissociated impairment of rostral sympathetic innervations and isolated segmental sweating on otherwise anhidrotic trunk. J Exp Med. 1999;188:95–102.
Nishimura J, Tamada Y, Iwase S, Kubo A, Watanabe D, Matsumoto Y. A case of lung cancer with unilateral anhidrosis and contralateral hyperhidrosis as the first clinical manifestation. J Am Acad Dermatol. 2011;65(2):438–40.
Smith CD. A hypothalamic stroke producing recurrent hemihyperhidrosis. Neurology. 2001;56:1394–6.
Hornberger J, Grimes K, Naumann M, Glaser DA, Lowe NJ, Naver H, et al. Recognition diagnosis, and treatment of primary focal hyperhidrosis. J Am Acad Dermatol. 2004;51(2):274–86.
Vary JC Jr. Selected disorders of skin appendages – acne, alopecia, hyperhidrosis. Med Clin N Am. 2015;99(6):1195–211.
Solish N, Bertucci V, Dansereau A, Hong HC, Lynde C, Lupin M, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33:908–23.
Hexsel D, Rodrigues TC, Soirefmann M, Zechmeister-Prado D. Recommendations for performing and evaluating the results of the minor test according to a sweating intensity visual scale. Dermatol Surg. 2010;36:120–2.
Steiner D. Quantitative sweats tests: iodine-starch and gravimetry. In: Almeida ART, Hexsel DM, editors. Hyperhidrosis and botulinum toxin. SĂ£o Paulo: Edition of authors; 2004. p. 59–61.
Bahmer F, Sachse M. Hyperhidrosis area and severity index. Dermatol Surg. 2008;34:1744–5.
French J, Gronseth G. Lost in a jungle of evidence: we need a compass. Neurology. 2008;71:1634–8.
Shelley WB, Hurley HJ Jr. Studies on topical antiperspirant control of axillary hyperhidrosis. Acta Derm Venereol. 1975;55:241–60.
Walling HW, Swick BL. Treatment options for hyperhidrosis. Am J Clin Dermatol. 2011;12:285–95.
Flanagan KH, Glaser DA. An open-label trial of the efficacy of 15% aluminium chloride in 2% salicylic acid gel base in the treatment of moderate-to-severe primary axillary hyperhidrosis. J Drugs Dermatol. 2009;8:477–80.
MacKenzie A, Burns C, Kavanagh G. Topical glycopyrrolate for axillary hyperhidrosis. Br J Dermatol. 2013;69:483–4.
Baker D. Topical glycopyrrolate spray 2% reduces axillary hyperhidrosis to a similar extent as Botox injections. Br J Dermatol. 2013;169(Suppl. 1):4.
Panting KJ, Alkali AS, Newman WD, Sharpe GR. Dilated pupils caused by topical glycopyrrolate for hyperhidrosis. Br J Dermatol. 2008;158:187–8.
Johnson C, Smereck J. Unilateral mydriasis due to a topical ‘antisweat’ preparation. J Emerg Med. 2013;44:673–5.
Madan V, Beck MH. Urinary retention caused by topical glycopyrrolate for hyperhidrosis. Br J Dermatol. 2006;155:634–5.
Glaser DA. Oral medications. Dermatol Clin. 2014;32:527–32.
Wolosker N, De Campos JRM, Kauffman P, et al. A randomized placebo controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012;55:1696–700.
Wolosker N, Schvartsman C, Krutman M. Efficacy and quality of life outcomes of oxybutynin for treating palmar hyperhidrosis in children younger than 14 years old. Pediatr Dermatol. 2014;31:48–53.
MillĂ¡n-Cayetano JF, Boz J, Rivas-Ruiz F, BlĂ¡zquez-SĂ¡nchez N, IbĂ¡Ă±ez CH, Troya-MartĂn M. Oral oxybutynin for the treatment of hyperhidrosis: outcomes after one-year follow-up. Australas J Dermatol 2017;58(2):e31–5.
Stolman LP. Hyperhidrosis: medical and surgical treatment. Eplasty. 2008;8:e22.
Stolman LP. Treatment of excess sweating of the palms by iontophoresis. Arch Dermatol. 1987;123:893–6.
Togel B, Greve B, Raulin C. Current therapeutic strategies for hyperhidrosis: a review. Eur J Dermatol. 2002;12:219–23.
Karakoc Y, Aydemir EH, Kalkan MT, Unal G. Safe control of palmoplantar hyperhidrosis with direct electrical current. Int J Dermatol. 2002;41:602–5.
Almeida AT, Cernea SS. Tratamento da hiperidrose. In: Hexsel D, Almeida AT, editors. Uso cosmĂ©tico da toxina botulĂnica. Porto Alegre: AGE; 2002. p. 226–7.
Hexsel DM, Soirefmann M, Rodrigues TC, do Prado DZ. Increasing the field effects of similar doses of Clostridium botulinum type A toxin-hemagglutinin complex in the treatment of compensatory hyperhidrosis. Arch Dermatol. 2009;145(7):837–40.
Hexsel D, Soirefmann M, Porto MD, Schilling-Souza J, Siega C. Fields of anhidrotic effects of abobotulinumtoxin A in patients with compensatory hyperhidrosis. Dermatol Surg. 2015;41:S93–S100.
Heckmann M, Ceballos-Baumann AO, Plewig G. Botulinum toxin a for axillary hyperhidrosis (excessive sweating). N Engl J Med. 2001;344:488–93.
Naumann M, Lowe NJ. Botulinum toxin type a in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323:596–9.
Odderson IR. Long-term quantitative benefits of botulinum toxin type A in the treatment of axillary hyperhidrosis. Dermatol Surg. 2002;28:480–3.
Simonetta Moreau M, Cauhepe C, Magues JP, Senard JM. A double-blind, randomized, comparative study of Dysport vs Botox in primary palmar hyperhidrosis. Br J Dermatol. 2003;149:1041–5.
Lowe NJ, Glaser DA, Eadie N, Daggett S, Kowalski JW, Lai PY. Botulinum toxin type a in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol. 2007;56:604–11.
Vadoud-Seyedi J, Simonart T. Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side-by-side, double-blind study. Br J Dermatol. 2007;156:986–9.
TalaricoFilho S, Mendonça do Nascimento M, Sperandeo de Macedo F, De Sanctis Pecora C. A double-blind, randomized, comparative study of two type a botulinum toxins in the treatment of primary axillary hyperhidrosis. Dermatol Surg. 2007;33:S44–50.
Gregoriou S, Rigopoulos D, Makris M, Liakou A, Agiosofitou E, Stefanaki C, Kontochristopoulos G. Effects of botulinum toxin-a therapy for palmar hyperhidrosis in plantar sweat production. Dermatol Surg. 2010 Apr;36(4):496–8.
Dressler D, Adib SF. Towards a dose optimisation of botulinum toxin therapy for axillary hyperhidrosis: comparison of different Botox(®) doses. J Neural Transm. 2013;120(11):1565–7.
Letada PR, Landers JT, Uebelhoer NS, et al. Treatment of focal axillary hyperhidrosis using a long pulsed Nd: YAG 1064 nm laser at hair reduction settings. J Drugs Dermatol. 2012;11:59–63.
Aydin F, Pancar GS, Senturk N, et al. Axillary hair removal with 1064-nm Nd:YAG laser increases sweat production. Clin Exp Dermatol. 2010;35:588–92.
Hong HC, Lupin M, O’Shaughnessy KF. Clinical evaluation of a microwave device for treating axillary hyperhidrosis. Dermatol Surg. 2012;38:728–35.
Lee S, Chang K, Suh D, et al. The efficacy of a microwave device for treating axillary hyperhidrosis and osmidrosis in Asians: a preliminary study. J Cosmet Laser Ther. 2013;15:255–9.
Glaser DA, Coleman WP, Fan LK, et al. A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study. Dermatol Surg. 2012;38:185–91.
Nestor MS, Park H. Safety and efficacy of micro-focused ultrasound plus visualization for the treatment of axillary hyperhidrosis. J Clin Aesthet Dermatol. 2014;7(4):14–21.
Feldmeyer L, Bogdan I, Moser A, Specker R, Kamarashev J, French LE, et al. Short- and long-term efficacy and mechanism of action of tumescent suction curettage for axillary hyperhidrosis. J Eur Acad Dermatol Venereol. 2015;29(10):1933–7.
Ojimba TA, Cameron AE. Drawbacks of endoscopic thoracic sympathectomy. Br J Surg. 2004;91:264–9.
Bell D, Jedynak J, Bell R. Predictors of outcome following endoscopic thoracic sympathectomy. ANZ J Surg. 2014;84:68–72.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Glossary
- Apocrine sweat glands 
-
Larger sweat glands that occur in hair follicles. They appear after puberty.
- Apoeccrine sweat glands 
-
Contain morphological features common to the eccrine and apocrine sweat glands.
- Eccrine sweat glands 
-
Small sweat glands that produce a fluid secretion without removing cytoplasm from the secreting cells and that are restricted to the human skin.
- Hyperhidrosis 
-
Sweating greater than necessary for the maintenance of normal body thermoregulation.
- Primary hyperhidrosis 
-
Excessive sweating in specific regions of the body and not caused by other medical conditions or by medications.
- Secondary hyperhidrosis 
-
Excessive sweating caused by medications or medical conditions.
- Sympathectomy 
-
Procedures that break the sympathetic innervation, thereby blocking stimulation of eccrine glands.
Rights and permissions
Copyright information
© 2018 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Hexsel, D., Camozzato, F.O. (2018). Hyperhidrosis. In: Bonamigo, R., Dornelles, S. (eds) Dermatology in Public Health Environments. Springer, Cham. https://doi.org/10.1007/978-3-319-33919-1_67
Download citation
DOI: https://doi.org/10.1007/978-3-319-33919-1_67
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33917-7
Online ISBN: 978-3-319-33919-1
eBook Packages: MedicineMedicine (R0)